Name: Clarithromycin
Brand: Selleck Chemicals
SKU: S2555
Availability: InStock
Rating: 5 (6 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Dehydrogenase HSP Transferase PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Casein Kinase
Other P450 (e.g. CYP17) Inhibitors	Apigenin Baicalein Naringenin Diosmetin Alizarin Sodium Danshensu Naringin Benzbromarone Orteronel Isosilybin

Solubility

In vitro
Batch:

DMSO : 18 mg/mL (24.06 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3mg/ml (4.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 60 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	747.95	Formula	C₃₈H₆₉NO₁₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	81103-11-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	A-56268			SMILES	CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	CYP3A4
In vitro	Clarithromycin suppresses this production in a dose-dependent manner in both monocytes and THP-1 cells. This compound regulates three other promoters that have either the NF-kappa B or the AP-1 binding sequences: two synthetic (pAP-1-Luc and pNF-kappa B-Luc) and one naturally occurring (ELAM-Luc). It suppresses NF-kappaB activation induced by TNF-alpha in U-937 and Jurkat cells in a concentration-related manner. The chemical inhibits NF-kappaB activation induced by TNF-alpha in U-937, Jurkat, and A549 cells and PBMC and by SEA in PBMC. It prevents NF-kappaB-dependent reporter gene expression in U-937 cells. This agent results in a significant suppression of production of each cytokine in 71% and a significant increase in 29% of the human monocytes. It inhibits tumor necrosis factor (TNF)-alpha-induced IL-8 gene expression in a dose- and incubation time-dependent manner. This compound represses AP-1 binding in TNF-alpha-treated BET-1A cells. It represses IL-8 gene transcription mainly via the AP-1 binding site in human bronchial epithelial cells. The substance suppresses IL-1 beta gene expression in human nasal epithelial cells stimulated by H. influenzae endotoxin (HIE). It suppresses intercellular adhesion molecule-1 gene expression in nasal fibroblasts stimulated by IL-1 beta. This chemical reduces DNA-binding activity of NF-kappa B in both human nasal epithelial cells and fibroblasts stimulated by HIE or IL-1 beta, respectively.
References	[1] https://pubmed.ncbi.nlm.nih.gov/12003967/ [2] https://pubmed.ncbi.nlm.nih.gov/11120942/ [3] https://pubmed.ncbi.nlm.nih.gov/10221415/ [4] https://pubmed.ncbi.nlm.nih.gov/10615065/ [5] https://pubmed.ncbi.nlm.nih.gov/10646728/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-20)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07485010	NOT_YET_RECRUITING	Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease	The University of Queensland	2027-04	PHASE2
NCT04415983	RECRUITING	Helicobacter Pylori Infection	Tanta University	2020-06-01	PHASE3
NCT04310930	RECRUITING	Pulmonary Disease Due to Mycobacteria (Diagnosis)	The University of Queensland	2020-03-02	PHASE2; PHASE3
NCT07104318	NOT_YET_RECRUITING	Helicobacter Pylori	VA Office of Research and Development	2026-10-01	PHASE3
NCT03236987	RECRUITING	Lung Infection; MAC Lung Disease	Centre Hospitalier Universitaire, Amiens	2018-02-05	PHASE3
NCT07341100	ACTIVE_NOT_RECRUITING	Ovarian Epithelial Cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	2026-01-16	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Clarithromycin P450 (e.g. CYP17) inhibitor

Chemical Structure

Molecular Weight: 747.95